Extract
长期的阿奇霉素治疗在Amazes审判中具有持续的症状哮喘的成年人的恶化(澳大利亚和新西兰临床试验登记处(ANZCTR),12609000197235)[1]。然而,参与者之间对治疗的反应是可变的,并且尚未确定经历大多数临床福利的人的特征。无法定义更响应的特定人群,这些群体限制了个性化这种治疗的能力,这是航空疾病管理的目标[2]。随着最近的研究识别气道Haemophilus influenzae作为哮喘亚组的候选标志物的定植[3,4],我们评估了吗?H. influenzaeabundance, measured using quantitative PCR (qPCR) [5, 6], predicted the ability of azithromycin therapy to reduce the incidence of acute asthma exacerbations.
抽象
痰Haemophilus influenzaeload predicts response to azithromycin in adults with persistent uncontrolled asthma: secondary findings from the AMAZES trialhttps://bit.ly/3f3tJ71
Acknowlegement
以下调查人员构成了令人惊叹的调查人员组:伊恩A.杨,约翰W. Upham,Paul N. Reynolds,Sandra Hodge,Alan L. James,Christine Jenkins,Matthew J. Peters,Melissa Baraket和Guy B. Marks。
脚注
Conflict of interest: S.L. Taylor has nothing to disclose.
Conflict of interest: K.L. Ivey has nothing to disclose.
Conflict of interest: P.G. Gibson reports personal fees for lectures from AstraZeneca, GlaxoSmithKline and Novartis, grants from AstraZeneca and GlaxoSmithKline, outside the submitted work.
Conflict of interest: J.L. Simpson has nothing to disclose.
利益冲突:G.B.罗杰斯没有什么可以披露的。
Support statement: This work was supported by the National Health and Medical Research Council (NHMRC project identifier 569246). Funding information for this article has been deposited with theCrossref Funder Registry.
- 收到January 29, 2020.
- Accepted2020年4月24日。
- 复制right ©ERS 2020